down arrow

Globus Medical, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3795772082
USD
88.74
0.99 (1.13%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

87.3089.05

52 Week

51.7994.93
Valuation
Technical
Day's Volume

CASH

424.94 k

Shareholding (Mar 2025)

FII

16.83%

Held by 209 FIIs

DII

45.22%

Held by 52 DIIs

Promoter

0.30%

How big is Globus Medical, Inc.?

22-Jun-2025

As of Jun 18, Globus Medical, Inc. has a market capitalization of $7.87 billion, with recent net sales of $2.51 billion and a net profit of $185.56 million.

Market Cap: As of Jun 18, Globus Medical, Inc. has a market capitalization of 7,870.96 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Globus Medical, Inc. reported net sales of 2,510.81 million and a net profit of 185.56 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 4,177.33 million and total assets of 5,251.75 million.

Read More

What does Globus Medical, Inc. do?

22-Jun-2025

Globus Medical, Inc. is a mid-cap medical device company specializing in products for musculoskeletal and spine disorders, with recent net sales of $598 million and a net profit of $75 million. The company has a market cap of approximately $7.87 billion.

Overview: <BR>Globus Medical, Inc. is a medical device company focused on developing products for patients with musculoskeletal disorders, specifically spine disorders, and operates in the Pharmaceuticals & Biotechnology industry within the mid-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 598 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 75 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 7,870.96 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.11 <BR>Return on Equity: 5.54% <BR>Price to Book: 1.93<BR><BR>Contact Details: <BR>Address: 2560 General Armistead Ave, AUDUBON PA: 19403-5214 <BR>Tel: 1 610 9301800 <BR>Website: http://www.globusmedical.com/

Read More

Who are in the management team of Globus Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Globus Medical, Inc. includes Executive Chairman David Paul, President and CEO David Demski, and several independent directors: David Davidar, Robert Douglas, Daniel Lemaitre, Ann Rhoads, and James Tobin.

As of March 2022, the management team of Globus Medical, Inc. includes the following individuals:<BR><BR>- Mr. David Paul, who serves as the Executive Chairman of the Board.<BR>- Mr. David Demski, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. David Davidar, who is an Independent Director.<BR>- Mr. Robert Douglas, who is also an Independent Director.<BR>- Mr. Daniel Lemaitre, another Independent Director.<BR>- Ms. Ann Rhoads, who serves as an Independent Director.<BR>- Mr. James Tobin, who is an Independent Director.<BR><BR>In summary, the management team consists of key executives and independent directors who guide the company's strategic direction.

Read More

Is Globus Medical, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Globus Medical, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -27.25% compared to 14.18%.

As of 3 October 2025, the technical trend for Globus Medical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on a weekly basis but bearish monthly, while the RSI is bearish weekly with no signal monthly. Moving averages are mildly bearish on a daily basis. Additionally, the Bollinger Bands and KST indicate a mildly bullish trend weekly but are mildly bearish monthly. <BR><BR>In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -27.25% versus 14.18% for the S&P 500, and a one-year return of -14.85% compared to 17.82% for the index.

Read More

Is Globus Medical, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, Globus Medical, Inc. is considered overvalued with a valuation grade of "attractive," reflected by a P/E ratio of 36 and a year-to-date return of -25.45%, significantly underperforming the S&P 500's 16.30%.

As of 31 October 2025, the valuation grade for Globus Medical, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 36, a Price to Book Value of 1.98, and an EV to EBITDA of 13.54. Comparatively, its peers such as Masimo Corp. with a P/E of 179.74 and Merit Medical Systems, Inc. with a P/E of 42.46 suggest that Globus Medical's valuation is relatively high.<BR><BR>In terms of performance, Globus Medical has underperformed against the S&P 500, with a year-to-date return of -25.45% compared to the index's 16.30%. This trend of underperformance, alongside its elevated valuation ratios, reinforces the conclusion that the stock is overvalued in the current market environment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company has a low Debt to Equity ratio (avg) at times

 
2

Low Debt Company with Strong Long Term Fundamental Strength

 
3

The company has declared Positive results for the last 3 consecutive quarters

4

With ROE of 5.54%, it has a expensive valuation with a 1.98 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8,042 Million (Small Cap)

stock-summary
P/E

36.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.05

stock-summary
Return on Equity

10.19%

stock-summary
Price to Book

1.87

Revenue and Profits:
Net Sales:
745 Million
(Quarterly Results - Jun 2025)
Net Profit:
203 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
47.19%
0%
47.19%
6 Months
48.74%
0%
48.74%
1 Year
5.13%
0%
5.13%
2 Years
91.62%
0%
91.62%
3 Years
18.4%
0%
18.4%
4 Years
40.75%
0%
40.75%
5 Years
46.07%
0%
46.07%

Globus Medical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Globus Medical Hits Day High with 35.94% Surge in Stock Price

Globus Medical Hits Day High with 35.94% Surge in Stock Price

Globus Medical, Inc. has seen notable stock activity, achieving an intraday high and significant weekly and monthly gains. The company reported a substantial year-on-year net profit increase and maintains strong operating cash flow. With a low debt-to-equity ratio and high institutional holdings, it demonstrates solid financial stability and market position.

Read More

Is Globus Medical, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Globus Medical, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 36, a Price to Book Value of 1.98, and an EV to EBITDA of 13.54. Comparatively, its peers such as Masimo Corp. with a P/E of 179.74 and Merit Medical Systems, Inc. with a P/E of 42.46 suggest that Globus Medical's valuation is relatively high. In terms of performance, Globus Medical has underperformed against the S&P 500, with a year-to-date return of -25.45% compared to the index's 16.30%. This trend of underperformance, alongside its elevated valuation ratios, reinforces the conclusion that the stock is overvalued in the current market environment....

Read More
Globus Medical Experiences Valuation Adjustment Amid Competitive Market Landscape

Globus Medical Experiences Valuation Adjustment Amid Competitive Market Landscape

Globus Medical, Inc. has recently adjusted its valuation, with its current price at $61.20. The company has faced challenges over the past year, reporting a return of -18.27%. Key financial metrics include a P/E ratio of 36 and a price-to-book value of 1.98, indicating its market position.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
28.58%
EBIT Growth (5y)
23.93%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.50
Tax Ratio
20.34%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
91.67%
ROCE (avg)
12.35%
ROE (avg)
7.98%
Valuation key factors
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
1.98
EV to EBIT
25.45
EV to EBITDA
13.54
EV to Capital Employed
2.11
EV to Sales
3.05
PEG Ratio
0.54
Dividend Yield
NA
ROCE (Latest)
8.27%
ROE (Latest)
5.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 132 Schemes (37.59%)

Foreign Institutions

Held by 209 Foreign Institutions (16.83%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 24.61% vs -9.01% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 168.61% vs 184.91% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "745.30",
          "val2": "598.10",
          "chgp": "24.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "196.90",
          "val2": "164.30",
          "chgp": "19.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-50.10",
          "val2": "-1.20",
          "chgp": "-4,075.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "202.80",
          "val2": "75.50",
          "chgp": "168.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "169.40%",
          "val2": "164.20%",
          "chgp": "0.52%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 60.62% vs 53.35% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -16.19% vs -35.38% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,519.40",
          "val2": "1,568.50",
          "chgp": "60.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "486.30",
          "val2": "346.60",
          "chgp": "40.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-66.30",
          "val2": "-68.70",
          "chgp": "3.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "103.00",
          "val2": "122.90",
          "chgp": "-16.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "92.20%",
          "val2": "128.70%",
          "chgp": "-3.65%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
745.30
598.10
24.61%
Operating Profit (PBDIT) excl Other Income
196.90
164.30
19.84%
Interest
0.00
0.00
Exceptional Items
-50.10
-1.20
-4,075.00%
Consolidate Net Profit
202.80
75.50
168.61%
Operating Profit Margin (Excl OI)
169.40%
164.20%
0.52%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 24.61% vs -9.01% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 168.61% vs 184.91% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,519.40
1,568.50
60.62%
Operating Profit (PBDIT) excl Other Income
486.30
346.60
40.31%
Interest
4.20
0.00
Exceptional Items
-66.30
-68.70
3.49%
Consolidate Net Profit
103.00
122.90
-16.19%
Operating Profit Margin (Excl OI)
92.20%
128.70%
-3.65%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 60.62% vs 53.35% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -16.19% vs -35.38% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Globus Medical, Inc. stock-summary
stock-summary
Globus Medical, Inc.
Pharmaceuticals & Biotechnology
Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. The Company's products fall under categories, which include Innovative Fusion and Disruptive Technologies. The Innovative Fusion category products include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. QUARTEX is its Occipito-Cervico-Thoracic (OCT) stabilization system. QUARTEX features a threading locking cap to enable low-torque. The Company's portfolio of approved and pipeline Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques.
Company Coordinates stock-summary
Company Details
2560 General Armistead Ave , AUDUBON PA : 19403-5214
stock-summary
Tel: 1 610 9301800
stock-summary
http://www.globusmedical.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."